nifekalant
Small moleculeexperimental
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia. It has the brand name Shinbit. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
2
Earliest trial started Jan 1, 2019 (NCT04209959)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Muscarinic acetylcholine receptor M2INHIBITOR
CHRM2 inhibitor
- Muscarinic acetylcholine receptor M3INHIBITOR
CHRM3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O- Mol. weight
- 405.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNifekalant ↗
- ChEMBLCHEMBL360861 ↗
Also known as
- nifekalant
- nifekalant
- nifekalant
- nifekalant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05169866 | Phase 3 | Mar 31, 2022 | Capital Medical University |
| NCT03855826 | Phase 4 | Jan 15, 2019 | Baili Pharmaceutical Group, People's Liberation Army of China |
| NCT04209959 | Phase 4 | Jan 1, 2019 | Nanchang University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 1 | 1 | 1 | 2019 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Nanchang University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1